Skip to main content
. Author manuscript; available in PMC: 2013 Nov 17.
Published in final edited form as: Hepatology. 2012 Jul 17;56(3):10.1002/hep.25629. doi: 10.1002/hep.25629

Figure 1.

Figure 1

Figure 1

Figure 1

a) Overall Kaplan Meier survival curve in all patients enrolled in our protocol (N=199) from presentation to death (N=90). Patients are censored at last follow-up if alive regardless of treatment received (intent to treat).

b) Kaplan Meier survival post-transplantation in all patients (N=131; N=36 deaths). Patients are censored at last follow-up if alive.

c) Recurrence-free Kaplan Meier survival in all patients (N=131) from transplantation to cholangiocarcinoma recurrence or death (N=38 recurrence or death). Patients are censored at last follow-up if alive and without recurrence.